Extended-release formulation for reducing the frequency of urination and method of use thereof
Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.
1. A method for reducing the frequency of urination, comprising: administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising:
an analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen,
wherein said pharmaceutical composition is formulated in an extended-release formulation and wherein said analgesic agent is administered orally at a daily dose of 0.1 μg to 5 mg.
2. The method of claim 1 , wherein said extended-release formulation comprises an enteric coating.
3. The method of claim 1 , wherein said analgesic agent is administered orally at a daily dose of 1 μg-1 mg.
4. The method of claim 1 , wherein said analgesic agent is administered orally at a daily dose of 1 μg-100 μg.
5. The method of claim 1 , wherein said analgesic agent is administered orally at a daily dose of 0.05 mg-5 mg.
6. The method of claim 1 , wherein said pharmaceutical composition further comprises a second analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, wherein said second analgesic agent is different from said first analgesic agent and wherein said second analgesic agent is administered orally at a daily dose of 0.1 μg-5 mg.
7. The method of claim 1 , wherein said pharmaceutical composition further comprises an antimuscarinic agent selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.
8. The method of claim 1 , further comprising:
administering to said subject a diuretic;
wherein said diuretic is administered at least 8 hours prior to bedtime, and wherein said pharmaceutical composition is administered within 2 hours prior to bedtime.
9. The method of claim 1 , wherein said pharmaceutical composition further comprises one or more antidiuretic agents.
10. A method for reducing the frequency of urination, comprising:
administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising:
a first component formulated for immediate-release; and
a second component formulated for extended-release,
wherein said first component and said second component each comprises an analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and wherein each of said first component and said second component is administered orally at a daily dose of 0.1 μg-5 mg.
11. The method of claim 10 , wherein said second component is coated with an enteric coating.
12. The method of claim 10 , wherein said first component and/or said second component further comprises an antimuscarinic agent selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.
13. The method of claim 10 , wherein said analgesic agent in each component is administered orally at a daily dose of 1 μg-1 mg.
14. The method of claim 10 , wherein said analgesic agent in each component is administered orally at a daily dose of 1 μg-100 μg.
15. The method of claim 10 , wherein said first component and/or said second component further comprises an antidiuretic agent.
16. The method of claim 15 , wherein said first component and/or said second component further comprises one or more antimuscarinic agents.
17. The method of claim 10 , further comprising:
administering to said subject a diuretic;
wherein said diuretic is administered at least 8 hours prior to bedtime, and wherein said pharmaceutical composition is administered within 2 hours prior to bedtime.
18. A pharmaceutical composition, comprising:
one or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen;
an antidiuretic agent; and
a pharmaceutically acceptable carrier,
wherein said pharmaceutical composition is formulated for extended-release in an oral dosage form, and wherein the total dosage of said one or more analgesic agents is 1 μg-5 mg.
19. The pharmaceutical composition of claim 18 , further comprising an antimuscarinic agent.
20. The pharmaceutical composition of claim 19 , wherein said antimuscarinic agent is selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.